PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-2.60%
Cash & equivalents declining -2.60% while CRVO's grows 53.54%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-2.60%
Below half of CRVO's -12.90%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.51%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-2.19%
Below half of CRVO's -14.01%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-4.69%
Both CRVO and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.67%
Higher Long-Term Investments Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
Both CRVO and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Below half of CRVO's -14.01%. Michael Burry sees a potential red flag for stagnation or capital shortage.
28.73%
Less than half of CRVO's -87.95%. David Dodd sees a more disciplined AP approach or lower volume.
27.69%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
38361.54%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
-27.69%
Less than half of CRVO's -2160.93%. David Dodd sees fewer expansions in other current obligations.
27.28%
Above 1.5x CRVO's 6.46%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
4.72%
50-75% of CRVO's 6.46%. Bruce Berkowitz notes a lower yoy liability increase.
4.00%
Above 1.5x CRVO's 0.05%. Michael Burry suspects heavy new equity expansion or dilution.
-3.83%
1.25-1.5x CRVO's -2.88%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.70%
Below half CRVO's -15.94%. Michael Burry sees potential underperformance in building shareholder capital.
-2.25%
Below half CRVO's -14.01%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.67%
Below half CRVO's -35.61%. Michael Burry suspects major underinvestment or forced divestment.
-0.77%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
2.64%
Less than half of CRVO's 134.92%. David Dodd sees better deleveraging or stronger cash buildup than competitor.